The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.
Emilio Bajetta
Research Funding - cooperative clinical trialsss
Laura Catena
Research Funding - Cooperative clinical trials
Nicola Fazio
Consultant or Advisory Role - Novartis
Research Funding - cooperate to trials
Sara Pusceddu
No relevant relationships to disclose
Pamela Biondani
No relevant relationships to disclose
Giusi Blanco
No relevant relationships to disclose
Sergio Ricci
No relevant relationships to disclose
Michele Aieta
No relevant relationships to disclose
Francesca Pucci
No relevant relationships to disclose
Monica Valente
No relevant relationships to disclose
Nadia Bianco
No relevant relationships to disclose
Fernanda Bellomo
No relevant relationships to disclose
Chiara Mauri
No relevant relationships to disclose
Pasquale Buonandi
No relevant relationships to disclose
Vincenza Roberto
No relevant relationships to disclose